#PulmCC Physician Scientist @uabmedicine| Director @ UAB-ILD program #curePF|@HarvardChanSPH alum|Wife and Triplet Mom #womeninmedicine| Tweets are mine.
Birmingham, AL
Joined November 2015
- Tweets885
- Following609
- Followers770
- Likes4.2K
Tejaswini Kulkarni retweeted
This is a wonderful recognition for CRISPR! Congrats to all the innovators for all these groundbreaking inventions.
We’re proud to share that we’ve been named on the @TIME Best Inventions of 2024 list! This list recognizes a wide variety of new products, software or services that are making a difference in the world. #TIMEBestInventions
Tejaswini Kulkarni retweeted
#CHEST2024 Recap: Experts discussed how to evaluate and manage clinical worsening in patients with PH-ILD.
Read more in CHEST Daily News: hubs.la/Q02VyD6P0
Tejaswini Kulkarni retweeted
Great talk at #ICLAF2024 by Prof Kulkarni
on phase 3 clinical trials in Pulmonary Fibrosis - provides insight on failure - hope for success
👏🏼👏🏼👏🏼@tkulkarn1 👏🏼👏🏼🙏🏼
Tejaswini Kulkarni retweeted
Excellent discussion on early initiation of anti-fibrotic therapy in Non-IPF fibrotic lung disease, led by @tkulkarn1 and Dr. Danoff.
Should our primary emphasis be on enhancing QoL? Active involvement of patients in decision-making processes is key!
#CHEST2024 #CHESTTrainees
Tejaswini Kulkarni retweeted
Join us for journal club Thursday, October 3rd, 10 am EST on "Microscopic Small Airway Abnormalities Identified in Early Idiopathic Pulmonary Fibrosis In Vivo Using Endobronchial Optical Coherence Tomography"
Register here: thoracic.zoom.us/meeting/reg…
Tejaswini Kulkarni retweeted
Wow! Boehringer-Ingelheim announces that Nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study - a decade after the first positive phase III trials for IPF. Cannot wait to see the full results but this EXCITING !!!
#CureIPF
boehringer-ingelheim.com/us/…
Tejaswini Kulkarni retweeted
To commemorate Pulmonary Fibrosis Awareness Month, we will be sharing brilliant Pulmonary Fibrosis research from Thorax over the last year #CurePF
This paper highlights the innovative REMAP-ILD concept for drug development in fibrotic ILDs @leticiakawano @IPFdoc
thorax.bmj.com/content/79/8/…
Tejaswini Kulkarni retweeted
Telomere length testing is a readily available clinical test for precision management of ILD. We describe the clinical impact of TL testing in ILD clinic including impact on pharmacologic management and genetic testing @journal_CHEST
journal.chestnet.org/article…
Tejaswini Kulkarni retweeted
Prof. Athol Wells presents elegant data from a recent multinational Delphi consensus that:
• Progression of ILD is progression irrespective of time since diagnosis
•“despite usual management” should be included in PPF definition
Important for future PPF guidelines.
#ATS2024
Tejaswini Kulkarni retweeted
Moments like this makes it worth coming to #ATS2024
…and a whole lot of good cheer with friends from all around the globe 🌏!!!
#LearningFromTheBest
#ATS2024
#MTWC
Tejaswini Kulkarni retweeted
Now please meet SUPER #ValerieQuinn, @REMAP_ILD project manager 🤩
Valerie rocks BIG TIME, you have no idea! Thanks, Valerie for your dedication to #REMAPILD!
I am so happy to meet you in person for the first time!
Ping @IPFdoc @tkulkarn1 @KerriBerriKerri
Tejaswini Kulkarni retweeted
…and a whole lot of good cheer with friends from all around the globe 🌏!!!
#LearningFromTheBest
#ATS2024
#MTWC
Tejaswini Kulkarni retweeted
#ATS2024 has been amazing!!! 🫁
Spectacular science and delightful mealtime research conversations with colleagues from all around the world about overcoming #PulmonaryFibrosis.
#FantasticSanDiego
#MakingProgressAtAllTimes
Tejaswini Kulkarni retweeted
For those interested in #ILD #multiomics #precisionsmedicine, come attend our midday symposium on Sun 05/19 12PM Room 24A-C. Will give overview of @nih_nhlbi @ThreeLakes_TLF @PFFORG PRECISIONS program and how to get involved
#ATS2024
Tejaswini Kulkarni retweeted
Here's a glimpse of the incredible individuals who contribute to the heart of CHEST. Celebrating #VolunteerAppreciationWeek with gratitude for all those (pictured or not) who give their time to advance medicine and improve patient care. Thank you! hubs.la/Q02twftk0
Tejaswini Kulkarni retweeted
I'm looking forward to speaking at @TheAtlantic's Health Summit on April 4! I hope some of you will join me in person in Boston or virtually. #AtlanticHealth
On April 4th at 10am ET, our CEO Dr. Samarth Kulkarni @CrisprSam will join @TheAtlantic's Health Summit to discuss the future of gene-editing technology. Learn more and register here: theatlantic.com/live/health-… #AtlanticHealth
Tejaswini Kulkarni retweeted
On April 4th at 10am ET, our CEO Dr. Samarth Kulkarni @CrisprSam will join @TheAtlantic's Health Summit to discuss the future of gene-editing technology. Learn more and register here: theatlantic.com/live/health-… #AtlanticHealth
Tejaswini Kulkarni retweeted
The devil might be on the steroid dose if previously used. Another question is what treatment should be continued after PLEX+RTX+IVIG.
I've been using this protocol in the last few months with encouraging results. I think this treatment option should also be open to other IIP.
Tejaswini Kulkarni retweeted
Trials like the EXAFIP RCTs and @tkulkarn1’s above have my huge respect. Just trying to get clinical samples in AEIPF prior to steroid administration is so difficult due to the strength of treatment dogma.
Managing to identify and recruit v.sick pts in that environment….